ClinicalTrials.gg
Active, not recruitingNCT06967805Updated Oct 15, 2026

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of MTX-463 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Mediar Therapeutics. Active, not recruiting at 59 sites in 11 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Mediar Therapeutics · Phase 2, Interventional, and Treatment

Updated Oct 15, 2026Now Active, not recruitingNo longer in Croatia+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
49th of 188
168 · median 61
Started
2025
with 10 others
Phase 2
82 of 236
13 open now
Primary completion
2027-08
later than 22 of 50 live
Registered
217th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 49th largest by enrollment of the 188 interventional ones that give a count, is one of 11 that started in 2025, is one of 82 in phase 2, reaches primary completion later than 22 of the 50 other live ones, and was the 217th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Read the detailed description

Participants with IPF who meet the study's inclusion and exclusion criteria will be randomly assigned in a 1:1 ratio to receive MTX-463 or a matching placebo by intravenous (IV) infusion. Concomitant use of one of the approved IPF therapies, pifenidone, nintedanib, or nerandomilast, is permitted, and it is expected that about half the study population will be on one of those medications. Participants randomized to the MTX-463 arm of the study will receive an IV infusion every 4 weeks, beginning at Day 0 and ending at Week 20. The End of Treatment Visit will occur at Week 24, 4 weeks after the final infusion; and a final Safety Follow-Up Visit will occur at Week 28, 8 weeks after the final infusion. Assessments of FVC will occur at Screening, Baseline, and at all subsequent treatment visits up to and including Week 24. L-PF assessments will be performed at Baseline and Week 24. Participants will have blood drawn for safety assessment and to assess WISP1 levels at Baseline and every 4 weeks throughout the study. Blood will be drawn for serum PK analyses relative to the first and last doses of MTX-463.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • MTX-463-I201
  • MTX-463
  • IPF
  • Idiopathic Pulmonary Fibrosis
  • Adult
  • Fibrosis
  • Monoclonal Antibody
  • MAB
  • FVC
  • WISPer
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with IPF of any gender ≥ 40 years of age at time of signing the .
  • Able to understand the study and provide signed, written informed consent.
  • Able to read and understand the language of the informed consent and other study-related materials.
  • Meet the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association (ATS/ERS/JRS/ALAT) 2019 criteria for the diagnosis of IPF; Diagnosed with IPF within 7 years of screening.
  • If a participant is on treatment with pirfenidone, nintedanib, or nerandomilast, the dose of the medication must be stable for ≥ 90 days prior to Screening with plans to maintain the same dose throughout the study. Use of any of these 3 agents in combination with each other is not permitted.
  • If a participant was on treatment with pirfenidone, nintedanib, or nerandomilast, and the agent has been discontinued, this must have occurred ≥ 30 days prior to Screening. At Screening, there must also be no plan to start either of these medications for the duration of the study. Participants newly diagnosed with IPF who, in the judgment of the treating physician, are considered in need of treatment with nintedanib, pirfenidone, or nerandomilast should not defer standard of care treatment and should be excluded from the study.
  • FVC of ≥ 45 percent predicted (pp) at screening.
  • DLCO of ≥ 25pp at screening.
  • Willing and able to complete all protocol required study visits and procedures.
  • Female participants of must have a negative serum pregnancy test at Screening.
  • Participants with must agree to use and follow medically approved highly effective methods of during treatment and until 5 half-lives or 125 days after the last dose of study drug, whichever is longer.
  • Male participants with female partners of childbearing potential must use condoms during the treatment and until 5 half-lives or 125 days after the last dose of study drug, whichever is longer.

Exclusion criteria

Exclusion Criteria:

  • Acute exacerbation of IPF within 6 months of Screening or during the Screening Period.
  • (FEV1)/FVC ratio of \<0.7 at Screening.
  • Requirement for continuous supplemental oxygen. Intermittent supplemental oxygen use (e.g., during exercise or sleep) is permitted.
  • Expected to receive a lung transplant within the study duration.
  • Current active bacterial infection or use of antibiotics for suspected lung infection in the 30 days prior to Screening.
  • Planned surgery within the study duration.
  • pulmonary hypertension.
  • Use of therapy (excluding ). If previously on such agents, they should have been discontinued for at least 5 half-lives or 90 days, whichever is longer, prior to Screening.
  • Use of systemic corticosteroids (prednisone or equivalent) at a dose > 10 mg once daily within 30 days of Screening.
  • Currently smoking or vaping.
  • Current known , or history of cancer, or lymphoproliferative disorder other than non-melanomatous skin cancers, within 2 years of Screening.
  • Current infection with , , or (HIV).
  • Currently pregnant, breast feeding, or planning to conceive for the length of the study.
  • History of severe depression, psychosis, or suicidal ideation, as determined by the Investigator, within 2 years of Screening.
  • Any clinically significant disease or laboratory abnormality detected at Screening that might interfere with a participant's ability to complete the study, on-study evaluations, or participant safety.
  • (AST) or alanine aminotransferase (ALT) > 2× (ULN) at Screening.
  • Presence of interstitial lung disease due to any cause other than IPF, clinically significant cardiovascular disease, or any other concurrent active medical condition determined by the Investigator to interfere with the participant's ability to complete the trial.
  • Known allergy to MTX-463 or any of its , or a history of a prior allergic reaction to a monoclonal antibody therapeutic.
  • Any prior use of MTX-463 or other therapy targeting WISP1.
  • Any other concurrent experimental agent or an active part of any other clinical study, unless they have stopped taking the product at least 5 half-lives or 30 days before Screening, whichever is longer.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    MTX-463

    MTX-463

    Biological: MTX-463

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • BiologicalMTX-463

    MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. To assess the effect of MTX-463 on the change from Baseline in forced vital capacity (FVC)

    Change from Baseline to Week 24 in Forced Vital Capacity (FVC)

    Time frame: 24 Weeks

Secondary outcomes

  1. To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of treatment emergent adverse events

    Incidence of treatment-emergent adverse events (TEAEs) from Baseline until Week 28 in each group

    Time frame: 28 Weeks

  2. To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of treatment related adverse events

    Incidence of treatment related adverse events from Baseline until Week 28 in each group

    Time frame: 28 Weeks

  3. To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of serious treatment emergent adverse events

    Incidence of serious treatment emergent adverse events from Baseline until Week 28 in each group

    Time frame: 28 Weeks

  4. To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of severe treatment emergent adverse events

    Incidence of severe treatment emergent adverse events from Baseline until week 28 in each group

    Time frame: 28 Weeks

  5. To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of treatment emergent abnormalities on clinical laboratory tests

    Incidence of treatment emergent abnormalities on clinical laboratory tests from Baseline until Week 28 in each group

    Time frame: 28 Weeks

  6. To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of abnormal findings on physical exam

    Incidence of abnormal findings on physical exam from baseline until Week 28 in each group

    Time frame: 28 Weeks

  7. To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of treatment discontinuations

    Incidence of treatment discontinuations from Baseline until Week 28 in each group

    Time frame: 28 Weeks

  8. To assess the effect of MTX-463 on the change from Baseline in the percent predicted FVC (FVCpp)

    Change from Baseline to Week 24 in the percent predicted FVC (FVCpp)

    Time frame: 24 Weeks

  9. To collect sparse pharmacokinetics (PK) of MTX-463 in participants with IPF

    Samples will be collected from Baseline until Week 24 to assess the trough serum concentrations of the study drug

    Time frame: 24 Weeks

Other outcomes

  1. To assess the development of antidrug antibodies (ADA) against MTX-463

    Samples will be collected from Baseline until Week 28 to assess the rate at which antibodies develop to the study drug

    Time frame: 28 Weeks

  2. To assess the effect of MTX-463 on the change from Baseline in FVC in participants on concomitant pirfenidone, nintedanib, or nerandomilast

    The change from Baseline to week 24 in the mean FVC (in ML) will be measured in each group in the subset of participants who enter the study on background IPF medications, pirfenidone, nintedanib, or nerandomilast

    Time frame: 24 Weeks

  3. To assess the effect of MTX-463 on the change from Baseline in FVC in participants not on concomitant pirfenidone, nintedanib, or nerandomilast

    The change from baseline to week 24 in the mean FVC (in ML) will be measured in each group in the subset of participants who enter the study not on any background IPF medications, pirfenidone, nintedanib, or nerandomilast

    Time frame: 24 Weeks

  4. To assess the effect of MTX-463 on the change from Baseline in the Living with Pulmonary Fibrosis (L-PF) Questionnaire total score

    Change from Baseline to Week 24 in L-PF total score. The L-PF is scored on a scale of 0-100, with higher numbers indicating greater impairment.

    Time frame: 24 Weeks

  5. To assess whether serum WNT-inducible signaling pathway protein 1 (WISP1) levels at Screening predict improved outcomes with MTX-463 treatment

    * Change from Baseline to Week 24 in total WISP1 levels * Change from Baseline to Week 24 in free WISP1 levels * Change from Baseline to Week 24 in FVC by free and total WISP1 screening quartiles

    Time frame: 24 Weeks

  6. To assess the effect of MTX-463 on the change from Baseline in percent predicted diffusing capacity of the lungs for carbon monoxide (DLCO)

    Change from Baseline to Week 24 in percent predicted DLCO

    Time frame: 24 Weeks

  7. To evaluate the time to disease progression as determined by change in FVC, IPF-related changes, or death

    Time to disease progression with progression being defined as ≥10% decline in FVC from Baseline, IPF related hospitalization, or death

    Time frame: 28 Weeks

  8. To assess the effect of MTX-463 on the PROLIFIC panel of biomarkers

    The mean change from Baseline to Week 24 in the level of each PROLIFIC panel biomarker (MMP-7, SP-D, KL-6, PAI-1, CA-19-9, CYFRA 21-1, CXCL13, sICAM1, CCL18, POSTN, CA-125, and TNC) in the serum will be measured in each group

    Time frame: 24 Weeks

  9. To assess the effect of MTX-463 on biomarkers of IPF

    The mean change from Baseline to Week 24 in the levels of each biomarker of IPF (TIMP-1, CCL2, Pro-C3, Pro-C6, C7M, and IL-6) in the serum will be measured in each group

    Time frame: 24 Weeks

  10. To assess the effect of MTX-463 on biomarkers of bone remodeling

    The mean change from Baseline to Week 24 in the levels of each biomarker of bone remodeling (procollagen type 1 N-terminal propeptide \[P1NP\] and C-terminal cross-linked telopeptide of type 1 collagen \[CTX\])

    Time frame: 24 weeks

07

Study locations

59 sites
  • WISPer Site in Birmingham, AL
    Birmingham, Alabama 35233, United States
  • WISPer site in Phoenix, AZ
    Phoenix, Arizona 85032, United States
  • WISPer site in Newport Beach, CA
    Newport Beach, California 92663, United States
  • WISPer Site in Palm Springs, CA
    Palm Springs, California 92262, United States
  • WISPer Site in Denver, CO
    Denver, Colorado 80206, United States
  • WISPer site in Loxahatchee, FL
    Loxahatchee Groves, Florida 33470, United States
  • WISPer Site in Atlanta, GA
    Atlanta, Georgia 30322, United States
  • WISPer site in Champaign, IL
    Champaign, Illinois 61822, United States
  • WISPer site in Kansas City, KS
    Kansas City, Kansas 66160, United States
  • WISPer site in Shreveport, LA
    Shreveport, Louisiana 71103, United States
  • WISPer Site in Baltimore, MD
    Baltimore, Maryland 21224, United States
  • WISPer Site in Boston, MA
    Boston, Massachusetts 02114, United States
  • WISPer Site in Ann Arbor, MI
    Ann Arbor, Michigan 48209, United States
  • WISPer site in New York, NY
    New York, New York 10032, United States
  • WISPer Site in Durham, NC
    Durham, North Carolina 27710, United States
  • WISPer site in Greensboro, NC
    Greensboro, North Carolina 27403, United States
  • WISPer site in Oklahoma City, OK
    Oklahoma City, Oklahoma 73104, United States
  • WISPer Site in Pittsburgh, PA
    Pittsburgh, Pennsylvania 15213, United States
  • WISPer Site in Charleston, SC
    Charleston, South Carolina 29425, United States
  • WISPer site in Dallas, TX
    Dallas, Texas 75204, United States
  • WISPer Site in Salt Lake City, UT
    Salt Lake City, Utah 84103, United States
  • WISPer Site in Milwaukee, WI
    Milwaukee, Wisconsin 53226, United States
  • WISPer Site in Buenos Aires, Argentina
    Buenos Aires, B1602DQD, Argentina
  • WISPer Site in Buenos Aires, Argentina
    Buenos Aires, C1199ABB, Argentina
  • WISPer Site in Cordoba, Argentina
    Córdoba, X5003DCE, Argentina
  • WISPer Site in Mendoza, Argentina
    Mendoza, M5500, Argentina
  • WISPer Site in San Miguel De Tucumán, Argentina
    San Miguel de Tucumán, T4000IAI, Argentina
  • WISPer site in Melbourne, Australia
    Melbourne, 3004, Australia
  • WISPer site in Midland, Australia
    Midland, 6056, Australia
  • WISPer site in Westmead, Australia
    Westmead, 2145, Australia
  • WISPer Site in Brussels, Belgium
    Brussels, 1200, Belgium
  • WISPer Site in Edegem, Belgium
    Edegem, 2650, Belgium
  • WISPer Site in Belo Horizonte, Brazil
    Belo Horizonte, 30110, Brazil
  • WISPer Site in Curitiba, Brazil
    Curitiba, 80060, Brazil
  • WISPer Site in Passo Fundo, Brazil
    Passo Fundo, 99010, Brazil
  • WISPer Site in Porto Alegre, Brazil
    Porto Alegre, 90035, Brazil
  • WISPer Site in São Bernardo Do Campo, Brazil
    São Bernardo do Campo, 09715, Brazil
  • WISPer Site in Sao Paulo, Brazil
    São Paulo, 05403, Brazil
  • WISPer Site in Calgary, Alberta
    Calgary, Alberta T2N 4Z5, Canada
  • WISPer site in Ajax, ON
    Ajax, Ontario L1S 2J5, Canada
  • WISPer site in Trois-Rivières, Quebec
    Trois-Rivières, Quebec G8T 7A1, Canada
  • WISPer Site in Nantes, France
    Nantes, 44800, France
  • WISPer Site in Nice, France
    Nice, 06001, France
  • WISPer Site in Rennes, France
    Rennes, 35033, France
  • WISPer Site in Abbotstown, Ireland
    Abbotstown, D15 X40D, Ireland
  • WISPer Site in Drogheda, Ireland
    Drogheda, A92VW28, Ireland
  • WISPer Site in Dublin, Ireland
    Dublin, D24 NR0A, Ireland
  • WISPer Site in Letterkenny, Ireland
    Letterkenny, F92 AE81, Ireland
  • WISPer Site in Nieuwegein, Netherlands
    Nieuwegein, 3435CM, Netherlands
  • WISPer Site in Rotterdam, Netherlands
    Rotterdam, 3015AA, Netherlands
  • WISPer Site in Barcelona, Spain
    Barcelona, 08017, Spain
  • WISPer Site in Barcelona, Spain
    Barcelona, 08036, Spain
  • WISPer Site in Lugo, Spain
    Lugo, 27003, Spain
  • WISPer Site in Madrid, Spain
    Madrid, 28223, Spain
  • WISPer Site in Santander, Spain
    Santander, 39008, Spain
  • WISPer Site in Birmingham, UK
    Birmingham, B15 2GW, United Kingdom
  • WISPer Site in Cambridge, UK
    Cambridge, CB2 0BB, United Kingdom
  • WISPer Site in Edinburgh, UK
    Edinburgh, EH16 4SA, United Kingdom
  • WISPer Site in Oxford, UK
    Oxford, OX3 7LE, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2027, 27 months after the start.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 27 months is close to that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
May 13, 2025
StartActual
May 5, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Sites
4 sites added, 16 sites removed; no longer in Croatia
Show 4 added (2 United States, 1 Argentina, 1 Brazil)
  • WISPer Site in Pittsburgh, PA · Pittsburgh, United States
  • WISPer Site in Milwaukee, WI · Milwaukee, United States
  • WISPer Site in Buenos Aires, Argentina · Buenos Aires, Argentina
  • WISPer Site in São Bernardo Do Campo, Brazil · São Bernardo do Campo, Brazil
Show 16 removed
  • WISPer Site in Los Angeles, CA · Los Angeles, United States
  • WISPer Site in Louisville, KY · Louisville, United States
  • WISPer Site in Detroit, MI · Detroit, United States
  • WISPer Site in Pittsburg, PA · Pittsburgh, United States
  • WISPer Site in Nashville, TN · Nashville, United States
  • WISPer Site in Wilwaukee, WI · Milwaukee, United States
  • WISPer Site in Rosario, Argentina · Rosario, Argentina
  • WISPer Site in Santa Fe, Argentina · Santa Fe, Argentina
  • WISPer Site in Santa Fe, Argentina · Santa Fe, Argentina
  • WISPer site in Greenslopes, Australia · Greenslopes, Australia
  • WISPer Site in Porto Alegre, Brazil · Porto Alegre, Brazil
  • WISP Site in São Bernardo Do Campo, Brazil · São Bernardo do Campo, Brazil
  • WISPer Site in Split · Split, Croatia
  • WISPer Site in Paris, France · Paris, France
  • WISPer Site in Barcelona, Spain · Barcelona, Spain
  • WISPer Site in Madrid, Spain 2 · Madrid, Spain
Oct 15, 2026
Enrollment
164 (estimated)→168 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Active, not recruiting
    4 sites added, 16 sites removed; no longer in Croatia
    Show 4 added (2 United States, 1 Argentina, 1 Brazil)
    • WISPer Site in Pittsburgh, PA · Pittsburgh, United States
    • WISPer Site in Milwaukee, WI · Milwaukee, United States
    • WISPer Site in Buenos Aires, Argentina · Buenos Aires, Argentina
    • WISPer Site in São Bernardo Do Campo, Brazil · São Bernardo do Campo, Brazil
    Show 16 removed
    • WISPer Site in Los Angeles, CA · Los Angeles, United States
    • WISPer Site in Louisville, KY · Louisville, United States
    • WISPer Site in Detroit, MI · Detroit, United States
    • WISPer Site in Pittsburg, PA · Pittsburgh, United States
    • WISPer Site in Nashville, TN · Nashville, United States
    • WISPer Site in Wilwaukee, WI · Milwaukee, United States
    • WISPer Site in Rosario, Argentina · Rosario, Argentina
    • WISPer Site in Santa Fe, Argentina · Santa Fe, Argentina
    • WISPer Site in Santa Fe, Argentina · Santa Fe, Argentina
    • WISPer site in Greenslopes, Australia · Greenslopes, Australia
    • WISPer Site in Porto Alegre, Brazil · Porto Alegre, Brazil
    • WISP Site in São Bernardo Do Campo, Brazil · São Bernardo do Campo, Brazil
    • WISPer Site in Split · Split, Croatia
    • WISPer Site in Paris, France · Paris, France
    • WISPer Site in Barcelona, Spain · Barcelona, Spain
    • WISPer Site in Madrid, Spain 2 · Madrid, Spain
    Enrollment 164 (estimated)→168 (actual)
    + 2 other changes: identifiers and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06967805
Lead sponsor
Mediar Therapeutics
Responsible party
Sponsor
First posted
May 13, 2025
Start date
May 5, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Todd Astor, MD
study chair · Mediar Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MTX-463

Start the discussion